

# Hypertensive Disorders of Pregnancy

Narges Farahi, MD, University of North Carolina School of Medicine, Chapel Hill, North Carolina

Fareedat Oluyadi, MD, Charles R. Drew University of Medicine and Science, Los Angeles, California

Andrea B. Dotson, MD, MSPH, Duke University School of Medicine, Durham, North Carolina

Hypertensive disorders of pregnancy are a major contributor to maternal morbidity and mortality in the United States and include chronic and gestational hypertension, preeclampsia, HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome, eclampsia, and chronic hypertension with superimposed preeclampsia. For patients with chronic hypertension, oral antihypertensive therapy should be initiated or titrated at a blood pressure threshold of 140/90 mm Hg or greater. Gestational hypertension and preeclampsia without severe features can be managed with blood pressure monitoring, laboratory testing for disease progression, antenatal testing for fetal well-being, and delivery at 37 weeks' gestation. The use of antihypertensive drugs to control nonsevere hypertension in the setting of gestational hypertension and preeclampsia does not improve outcomes and is not recommended. Antihypertensive therapy should be initiated expeditiously for acute-onset severe hypertension to prevent hemorrhagic stroke. Preeclampsia with severe features requires immediate stabilization and inpatient treatment with magnesium sulfate for seizure prophylaxis and antenatal corticosteroids (if preterm). Patients in the preterm period should receive antenatal corticosteroids without delaying delivery to complete courses. Hypertensive disorders of pregnancy can worsen or initially present after delivery and account for up to 44% of pregnancy-related deaths in the first six days postpartum. Patients should be monitored closely in the early postpartum period. Hypertensive disorders of pregnancy are linked to poor long-term maternal and fetal outcomes, including increased maternal lifetime risk of cardiovascular disease. Daily low-dose aspirin therapy starting at 12 to 16 weeks' gestation is safe and effective for reducing the risk of preeclampsia for patients with risk factors. (*Am Fam Physician*. 2024;109(3):251-260. Copyright © 2024 American Academy of Family Physicians.)

**Hypertensive disorders** of pregnancy affect 1 in 7 hospital deliveries in the United States, are strongly associated with maternal complications, and account for 7% of pregnancy-related deaths.<sup>1-3</sup> Hypertensive disorders of pregnancy, which include chronic hypertension and pregnancy-associated hypertension (gestational hypertension, preeclampsia, HELLP [hemolysis, elevated liver enzymes, and low platelet count] syndrome, eclampsia, chronic hypertension with superimposed preeclampsia), increased in prevalence from 2017 to 2019.<sup>1,4</sup> Pregnancy-associated hypertension more than doubles the risk of peripartum coronary disease, cardiomyopathy, and stroke, and accounts for 44% of maternal deaths in the first six days following delivery.<sup>4-6</sup>

Preeclampsia is a multisystem disease process with pathogenesis involving maternal and placental pathways.<sup>2,5</sup> Non-modifiable risk factors for developing hypertensive disorders of pregnancy include genetic factors; reproductive history, including in vitro fertilization; and certain patient demographics.<sup>4,6</sup> Modifiable risk factors for preeclampsia reflect

cardiovascular risk and include obesity, dyslipidemia, diabetes mellitus, kidney disease, and chronic hypertension.<sup>2,5,7,8</sup> Placental influences begin in early pregnancy with abnormal placentation and spiral artery remodeling, leading to decreased uteroplacental perfusion and oxidative stress.<sup>6,7,9,10</sup> Pregnancy, a natural cardiac stress test, can also reveal underlying endothelial dysfunction.<sup>6,7</sup>

There are significant racial and ethnic disparities in the prevalence of hypertensive disorders of pregnancy. Non-Hispanic Black women have an up to five times higher risk of preeclampsia compared with non-Hispanic White women, are more likely to experience complications from hypertensive disorders of pregnancy, and have a threefold increased risk of inpatient maternal mortality after risk factor adjustment.<sup>1,4,11,12</sup> Multiple factors likely contribute to these disparities, including a higher prevalence of risk factors, less access to care, lower-quality care, underrepresentation in research, racial bias in health care, and the physiologic effect of stress from racism.<sup>1,5,13-15</sup>

## Diagnosis

Hypertensive disorders of pregnancy span the entire reproductive period from preconception to postpartum (*Figure 1*). Chronic hypertension can present before pregnancy,

**CME** This clinical content conforms to AAFP criteria for CME.

See CME Quiz on page 205.

**Author disclosure:** No relevant financial relationships.

## HYPERTENSIVE DISORDERS OF PREGNANCY

before 20 weeks' gestation, or during pregnancy without resolving postpartum.<sup>4,16</sup> Preeclampsia refers to new-onset hypertension after 20 weeks' gestation with proteinuria or end-organ dysfunction. Gestational hypertension describes new-onset hypertension after 20 weeks without proteinuria or end-organ dysfunction. When a patient with gestational hypertension or preeclampsia has severe-range blood pressure (160 mm Hg or greater systolic or 110 mm Hg or greater diastolic on at least two measurements) or end-organ involvement, the diagnosis shifts to preeclampsia with severe features.<sup>7</sup> Superimposed preeclampsia is

when a person with chronic hypertension has new-onset proteinuria or severe features, including acutely worsening or resistant hypertension. HELLP syndrome is a severe form of preeclampsia that involves hemolysis, liver dysfunction, and thrombocytopenia.<sup>7</sup> *Table 1* describes diagnostic criteria for hypertensive disorders of pregnancy.<sup>4,7,16,17</sup>

### CHRONIC HYPERTENSION

The diagnostic threshold for hypertension in pregnancy is a systolic blood pressure of 140 mm Hg or greater or a diastolic blood pressure of 90 mm Hg or greater on two measurements at least four hours apart.

Severe-range blood pressure quickly confirms the diagnosis, and treatment should be expedited.<sup>4</sup> One study found that pregnant women with a systolic blood pressure of 130 to 139 mm Hg or diastolic blood pressure of 80 to 89 mm Hg are at greater risk of gestational diabetes, preterm birth, and infant neonatal intensive care admissions compared with those who have normal blood pressure.<sup>18,19</sup> Although 20 weeks' gestation is conventionally used to distinguish chronic from gestational hypertension, a retrospective study found that 39% of patients with normal blood pressure before pregnancy developed hypertension without proteinuria before 20 weeks that resolved postpartum. Of patients with chronic hypertension, up to 50% develop superimposed preeclampsia.<sup>4,11</sup>

### GESTATIONAL HYPERTENSION AND PREECLAMPSIA

Pregnancy-associated hypertension represents a spectrum of illnesses that have an onset after 20 weeks' gestation. Screening recommendations focus on blood pressure monitoring during pregnancy.<sup>20</sup> Biomarkers and uterine artery Doppler ultrasonography have limited use in predicting preeclampsia.<sup>2,7</sup> Gestational hypertension with severe-range blood pressure has the same risk as preeclampsia with severe features and should be treated accordingly.<sup>4</sup> Up to one-half of women with gestational hypertension develop


### SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation	Evidence rating	Comments
In pregnant patients with gestational hypertension who develop severe-range blood pressure ( $\geq 160$ mm Hg systolic or 110 mm Hg diastolic), preeclampsia with severe features should be diagnosed and managed. <sup>4,7</sup>	<b>C</b>	Expert opinion and consensus guidelines
Pregnant patients with chronic hypertension should be treated to a blood pressure goal of < 140/90 mm Hg to reduce pregnancy outcomes without affecting fetal growth. <sup>11</sup>	<b>B</b>	Single high-quality RCT
Pregnant patients with gestational hypertension or preeclampsia without severe features should have a planned delivery at 37 weeks' gestation. <sup>7,24</sup>	<b>C</b>	Consensus guidelines
For pregnant patients who have preeclampsia with severe features between 24 and 34 weeks' gestation, inpatient expectant management to 34 weeks with close monitoring is recommended in the absence of deteriorating maternal or fetal status. <sup>7,24</sup>	<b>C</b>	Consensus guidelines
Acute episodes of severe hypertension in pregnant and postpartum patients should be treated within 30 to 60 minutes with intravenous labetalol or hydralazine or oral nifedipine. <sup>4,7,29</sup>	<b>C</b>	Consensus guidelines
Magnesium sulfate is the treatment of choice to prevent eclamptic seizures in pregnant women who have preeclampsia with severe features. <sup>25</sup>	<b>A</b>	RCTs and systematic reviews
Low-dose aspirin (81 mg per day) initiated after 12 weeks' gestation until delivery is recommended to decrease the risk of developing preeclampsia among women who are at risk. <sup>5,35</sup>	<b>B</b>	Systematic review of high-quality studies for U.S. Preventive Services Task Force

RCT = randomized controlled trial.

**A** = consistent, good-quality patient-oriented evidence; **B** = inconsistent or limited-quality patient-oriented evidence; **C** = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to <https://www.aafp.org/afpsort>.

FIGURE 1



**Note:** The length of arrow corresponds to the possible temporal range of presentation during pregnancy.

HELLP = hemolysis, elevated liver enzymes, and low platelet count.

\*—Within 48 hours of birth.

†—Between 48 hours and six weeks after delivery.

‡—With or without severe features.

§—Patients who present before 20 weeks' gestation with hypertension that persists for 12 weeks postpartum meet the criteria for chronic hypertension. This diagnosis may be superimposed with other hypertensive disorders of pregnancy later in the prenatal period (i.e., chronic hypertension with superimposed preeclampsia with or without severe features).

### Hypertensive disorders of pregnancy from preconception to postpartum.

preeclampsia, and the risk is higher when gestational hypertension presents before 32 weeks.<sup>7</sup>

### HELLP SYNDROME

HELLP syndrome is a severe form of preeclampsia associated with high morbidity and mortality. Malaise and right upper quadrant pain occur in 90% of patients with HELLP. Rapid clinical deterioration is a characteristic of HELLP. All components of the diagnostic criteria are necessary and distinguish HELLP from conditions such as preeclampsia complicated by disseminated intravascular coagulation, acute fatty liver disease of pregnancy, or thrombotic thrombocytopenic purpura. Additionally, 15% of patients with HELLP do not have hypertension or proteinuria, and up to one-third present in the postpartum period.<sup>7,21</sup>

### ECLAMPSIA

Eclampsia is a new-onset tonic-clonic, focal, or multifocal seizure in a pregnant or postpartum patient with a hypertensive disorder of pregnancy and without an alternative diagnosis for seizure. Eclampsia is a primary cause of maternal death globally.<sup>7</sup> One-half of eclampsia cases present before labor, with the other half presenting in the intrapartum or postpartum period. Eclamptic seizures can occur without warning; however, 80% are preceded by neurologic symptoms, including headaches, visual disturbances, and altered cognition.<sup>22</sup>

### POSTPARTUM HYPERTENSION

Although preeclampsia typically begins to resolve after delivery, patients can experience significant hypertension-related morbidity and mortality postpartum, especially in the first 48 hours following delivery. Postpartum hypertension is most common in patients with hypertension during pregnancy but can develop as new-onset hypertension or preeclampsia up to six weeks after delivery.<sup>7,17</sup> Notably, 1 in 5 eclamptic seizures initially presents postpartum, and 15% occur before preeclampsia is recognized.<sup>22</sup>

### Evaluation and Management

Evaluation and management of hypertensive disorders of pregnancy are summarized in *Table 2*.<sup>4,7,11,16,23-27</sup>

### CHRONIC HYPERTENSION

When hypertension is diagnosed before 20 weeks' gestation, cardiac function is a primary concern. Patients with long-standing hypertension (typically 10 years or longer but depends on severity and age at onset) are at risk of heart disease, including hypertrophy, cardiomegaly, and ischemic disease. Clinical evaluation includes a cardiovascular examination for potential cardiac dysfunction. Electrocardiography is recommended for patients older than 30 years and those with at least four years of poorly controlled disease. Echocardiography is warranted if electrocardiography findings are abnormal.<sup>4</sup> A baseline laboratory evaluation at the

TABLE 1

### Diagnostic Criteria for Hypertensive Disorders of Pregnancy

Disorder	Reproductive period	Diagnostic criteria
Chronic hypertension	Preconception, $\leq 20$ weeks' gestation, $> 12$ weeks postpartum	$\geq 140/90$ mm Hg twice at least four hours apart or $\geq 160/110$ mm Hg once
Gestational hypertension	$> 20$ weeks' gestation	$\geq 140/90$ mm Hg twice at least four hours apart without evidence of proteinuria or severe features
Preeclampsia without severe features	$> 20$ weeks' gestation, postpartum	$\geq 140/90$ mm Hg twice at least four hours apart with proteinuria $\geq 300$ mg per 24 hours or urine protein/creatinine ratio $\geq 0.3$ mg per dL
Preeclampsia with severe features	$> 20$ weeks' gestation, postpartum	Hypertension associated with any of the following:  Elevated blood pressure ( $\geq 160$ mm Hg systolic or $\geq 110$ mm Hg diastolic) twice at least four hours apart  Creatinine $> 1.1$ mg per dL or $>$ twice baseline  Elevated liver function tests (aspartate transaminase or alanine transaminase $>$ twice the upper limit of normal)  Platelets $< 100 \times 10^3$ per $\mu$ L ( $100 \times 10^9$ per L)  Right upper quadrant or epigastric pain  New headache  Vision changes  Pulmonary edema
Chronic hypertension with superimposed preeclampsia (with or without severe features)	$> 20$ weeks' gestation, postpartum	Chronic hypertension with new-onset proteinuria (or a sudden increase in proteinuria if present at baseline) or Development of severe features, including worsening or resistant hypertension (especially acutely)
HELLP syndrome	$> 20$ weeks' gestation, postpartum	Must have all of the following:  Hemolysis (elevated lactate dehydrogenase $\geq 600$ U per L)  Elevated aspartate transaminase or alanine transaminase $\geq$ twice the upper limit of normal  Platelets $< 100 \times 10^3$ per $\mu$ L
Eclampsia	$> 20$ weeks' gestation, postpartum	Tonic-clonic, focal, or multifocal seizures
Postpartum hypertension	New-onset within six weeks after delivery	$\geq 140/90$ mm Hg twice at least four hours apart  Immediate: if hypertension occurs within 48 hours after delivery  Delayed: if hypertension occurs between 48 hours and six weeks after delivery

HELLP = hemolysis, elevated liver enzymes, and low platelet count.

\*—Seizures can occur without hypertension or severe features of preeclampsia and with a normal blood pressure.

Information from references 4, 7, 16, and 17.

initial prenatal visit or after diagnosis should include a urine protein/creatinine ratio or 24-hour urine protein measurement, complete blood count, and serum creatinine, blood urea nitrogen, serum potassium, aspartate transaminase, and alanine transaminase testing.<sup>4</sup>

Oral antihypertensive therapy should be initiated or titrated when blood pressure is 140/90 mm Hg or greater. A treatment threshold of 140/90 mm Hg reduces adverse pregnancy outcomes compared with 160/105 mm Hg (number needed to treat [NNT] = 15; 95% CI, 9.4 to 33.7) without affecting fetal growth.<sup>11</sup> Treatment for a systolic blood pressure of 130 to 139 mm Hg or diastolic blood pressure of 80 to 89 mm Hg may be appropriate when patients have underlying cardiovascular comorbidities.<sup>4</sup> Labetalol and extended-release nifedipine are first-line oral medications for chronic hypertension in pregnancy.<sup>4,11</sup> Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers should be avoided because of their teratogenic effects. Thiazide diuretics may be continued when used before pregnancy and can be added as second- or third-line medications (Table 3).<sup>4,16</sup>

Chronic hypertension is associated with fetal growth restriction, and thus third-trimester ultrasonography is recommended.<sup>4</sup> Subsequent ultrasonography may be recommended based

## HYPERTENSIVE DISORDERS OF PREGNANCY

**TABLE 2**

### Evaluation and Management of Hypertensive Disorders of Pregnancy

Disorder	Evaluation	Blood pressure treatment	Antenatal surveillance	Timing of delivery	Other considerations
Chronic hypertension	Baseline CBC, BUN, serum creatinine, electrolytes, aspartate transaminase/alanine transaminase, urine protein/creatinine, electrocardiography or echocardiography (as indicated)	Initiate or titrate medication if blood pressure $\geq$ 140/90 mm Hg	Third-trimester growth ultrasonography	Controlled, not requiring medication: 38 weeks 0 days' to 39 weeks 6 days' gestation Controlled, on medication: 37 weeks 0 days' to 39 weeks 6 days' gestation	—
Gestational hypertension	Initial: CBC, serum creatinine, aspartate transaminase/alanine transaminase, LDH, urine protein/creatinine After diagnosis: office blood pressure measurement one or two times per week Weekly tests: CBC, serum creatinine, aspartate transaminase/alanine transaminase, urine protein/creatinine	No	Growth ultrasonography every three to four weeks Nonstress test, biophysical profile or modified biophysical profile one or two times per week Weekly amniotic fluid assessment	37 weeks 0 days' gestation or at diagnosis if diagnosed later	For severe features or sustained blood pressure $\geq$ 160/110 mm Hg, then diagnose and manage as preeclampsia with severe features
Preeclampsia (including superimposed) without severe features	Initial: CBC, serum creatinine, aspartate transaminase/alanine transaminase, LDH, urine protein/creatinine After diagnosis: office blood pressure measurement one or two times per week Weekly tests: CBC, serum creatinine, aspartate transaminase/alanine transaminase	No	Growth ultrasonography every three to four weeks Nonstress test, biophysical profile, or modified biophysical profile one to two times per week Weekly amniotic fluid assessment	37 weeks 0 days' gestation or at diagnosis if diagnosed later	—
Preeclampsia (including superimposed) with severe features	Initial: CBC, serum creatinine, aspartate transaminase/alanine transaminase, LDH, urine protein/creatinine Inpatient management from diagnosis until after delivery	Initiate or titrate medications if blood pressure $\geq$ 160/110 mm Hg	Growth ultrasonography every three to four weeks Inpatient antenatal surveillance with daily nonstress tests from diagnosis	34 weeks 0 days' gestation or at diagnosis if diagnosed later (earlier if contraindication to expectant management)	Seizure prophylaxis (magnesium sulfate) Antenatal corticosteroids if < 34 weeks' gestation 34 weeks 0 days' to 36 weeks 6 days' gestation if candidate for late-preterm steroids

*continues*

BUN = blood urea nitrogen; CBC = complete blood count; HELLP = hemolysis, elevated liver enzymes, and low platelet count; LDH = lactate dehydrogenase.

**TABLE 2** (continued)

**Evaluation and Management of Hypertensive Disorders of Pregnancy**

Disorder	Evaluation	Blood pressure treatment	Antenatal surveillance	Timing of delivery	Other considerations
HELLP syndrome	Initial: CBC, BUN, serum creatinine, aspartate transaminase/alanine transaminase, LDH, urine protein/creatinine  Inpatient management from diagnosis until after delivery	Initiate or titrate medications if blood pressure $\geq 160/110$ mm Hg	Inpatient monitoring	Plan for delivery after maternal stabilization (via induction of labor or cesarean delivery)	Seizure prophylaxis (magnesium sulfate)  Antenatal corticosteroids < 34 weeks' gestation 34 weeks 0 days' to 36 weeks 6 days' gestation if candidate for late-preterm steroids
Eclampsia	Inpatient management from diagnosis until after delivery	Initiate or titrate medications if blood pressure > 160/110 mm Hg	Inpatient monitoring	Plan for delivery after maternal stabilization (via induction of labor or cesarean delivery)	Treat seizures with magnesium sulfate  Airway protection, prevent maternal injury
Postpartum hypertension	If new onset, check CBC, serum creatinine, aspartate transaminase/alanine transaminase, LDH, urine protein/creatinine to evaluate for postpartum preeclampsia	Threshold to initiate oral antihypertensive medications $\geq 150/100$ mm Hg	—	—	Seizure prophylaxis (magnesium sulfate) if new-onset postpartum preeclampsia with severe features

BUN = blood urea nitrogen; CBC = complete blood count; HELLP = hemolysis, elevated liver enzymes, and low platelet count; LDH = lactate dehydrogenase.

Information from references 4, 7, 11, 16, and 23-27.

on the initial growth assessment. Antenatal fetal testing with a nonstress test, biophysical profile, or modified biophysical profile, including a nonstress test and an assessment of amniotic fluid volume, is recommended for patients with chronic hypertension requiring medications or associated with conditions affecting fetal outcomes.<sup>3,23</sup> For patients with chronic hypertension requiring medications, weekly antenatal testing starting at 32 weeks' gestation is recommended.<sup>23</sup> Timing of delivery should be based on a balance of maternal, fetal, and neonatal risks and range from 37 to 39 weeks' gestation for uncomplicated chronic hypertension.<sup>4,16</sup>

**GESTATIONAL HYPERTENSION AND PREECLAMPSIA WITHOUT SEVERE FEATURES**

After the initial diagnosis, the evaluation for patients with gestational hypertension and preeclampsia without severe features includes at least weekly office visits with blood pressure monitoring, symptom assessment, urine protein measurement to assess for preeclampsia, and laboratory evaluation to assess for severe features.<sup>7</sup> Although there are limited data for the timing and interval of antenatal fetal surveillance, testing is recommended because of the risk of

fetal growth restriction and death. The American College of Obstetricians and Gynecologists suggests fetal testing once or twice per week and weekly assessment of amniotic fluid volume.<sup>7,23</sup> Growth ultrasonography is recommended at diagnosis and every three to four weeks. In contrast with chronic hypertension, the use of antihypertensive drugs for nonsevere hypertension does not alter disease progression or improve outcomes and is not recommended.<sup>7</sup> Delivery is recommended at 37 weeks' gestation or at the time of diagnosis if after 37 weeks.<sup>7,24</sup>

**PREECLAMPSIA WITH SEVERE FEATURES**

Preeclampsia with severe features is associated with significant morbidity and rapid disease progression, and inpatient management is required from diagnosis until after delivery. When severe features are diagnosed at 34 weeks' gestation or later, delivery is recommended after maternal stabilization.<sup>7</sup> If severe features are diagnosed before 34 weeks' gestation, inpatient expectant management can be considered with serial maternal and fetal surveillance to delay delivery to 34 weeks. Progression to delivery is recommended if maternal or fetal status deteriorates<sup>7,24</sup> (Table 4').

## HYPERTENSIVE DISORDERS OF PREGNANCY

Due to the risk of cardiac events, renal injury, and ischemic or hemorrhagic stroke, antihypertensive therapy should be initiated within 30 to 60 minutes if acute-onset severe hypertension persists for 15 minutes.<sup>4,7</sup> First-line treatments for acute severe hypertension include intravenous labetalol, intravenous hydralazine, and oral immediate-release nifedipine, which is particularly useful when intravenous access has not been established<sup>7</sup> (Table 3<sup>4,16</sup>).

Magnesium sulfate helps prevent eclamptic seizures (NNT = 100) and placental abruption (NNT = 100) in preeclampsia with severe features.<sup>25</sup> For patients who have preeclampsia with severe features, intravenous magnesium sulfate is initiated with a loading dose of 4 to 6 g followed by a maintenance

infusion of 1 to 2 g per hour. Close monitoring of respiratory status, urine output, mental status, and reflexes is required to assess for potential magnesium toxicity.<sup>7,24</sup> Early signs of toxicity include the loss of deep tendon reflexes, and severe toxicity can present with respiratory depression, apnea, and cardiac arrest.<sup>7,24,25</sup>

### HELLP SYNDROME

For patients with HELLP syndrome, delivery at a tertiary care center is recommended at the time of diagnosis.<sup>7,21</sup> Just as magnesium sulfate is used for preeclampsia with severe features, it should be initiated for seizure prophylaxis.<sup>24</sup> A Cochrane review including limited studies of high-dose steroids found that they were not beneficial for HELLP syndrome.<sup>28</sup> Laboratory testing (complete blood count, lactate dehydrogenase, blood urea nitrogen, creatinine, aspartate transaminase, alanine transaminase) should be performed at least every 12 hours and continued postpartum until levels improve or stabilize.<sup>7</sup>

### ECLAMPSIA

Treatment of eclampsia includes protecting the maternal airway, avoiding injury, and promptly initiating magnesium sulfate. Compared with other anticonvulsants, magnesium sulfate is more effective for treating eclamptic seizures, preventing recurrent seizures, and decreasing mortality. The addition of other medications is not beneficial. For patients who received a loading dose of magnesium sulfate for prophylaxis, an additional 2-4 g bolus should be administered after a seizure. [corrected] For other patients, a loading dose of 4 to 6 g should be administered over 20 minutes.<sup>7,25</sup>

### Mode of Delivery

Vaginal delivery is preferred for patients with chronic hypertension, gestational hypertension, and preeclampsia without severe features in the absence of specific indications for cesarean delivery.<sup>7</sup> For patients who have preeclampsia with severe features, induction of labor is a reasonable option; however, cesarean delivery

**TABLE 3**

### Pharmacologic Management of Hypertension During Pregnancy

Medication	Dosage	Frequency	Comments
<b>Treatment of chronic hypertension</b>			
Labetalol (first-line)	200 to 2,400 mg per day orally	Divided doses every 8 to 12 hours	Avoid with uncontrolled asthma, cardiomyopathy
Nifedipine, extended-release (first-line)	30 to 120 mg per day orally	Once daily	May cause tachycardia
Methyldopa	250 to 3,000 mg per day orally	Divided doses every 6 to 12 hours	May be less effective; may cause sedation
Hydrochlorothiazide	12.5 to 25 mg per day orally	Once daily	May cause dehydration, electrolyte abnormalities
<b>Rapid treatment of severe persistent hypertension</b>			
Nifedipine, immediate-release	Starting dose: 10 mg orally Increase to 20 mg for up to 2 more doses	20-minute intervals	Transition to labetalol or hydralazine if still severe
Labetalol	Starting dose: 20 mg intravenously Increase to 40 mg then 80 mg if still severe (maximum cumulative dose = 300 mg)	10-minute intervals	Transition to hydralazine or oral nifedipine if still severe
Hydralazine	Starting dose: 5 mg intravenously Give additional 5 to 10 mg (maximum cumulative dose = 20 mg)	20-minute intervals	Transition to labetalol or oral nifedipine if still severe

Information from references 4 and 16.

TABLE 4

**Indications for Expedient Delivery in Preeclampsia With Severe Features at Less Than 34 Weeks' Gestation**

**Maternal**

- Abruptio placentae
- Disseminated intravascular coagulation
- Eclampsia
- HELLP syndrome
- Myocardial infarction
- Persistent severe symptoms (neurologic or gastrointestinal)
- Pulmonary edema
- Renal insufficiency
- Stroke

**Fetal**

- Abnormal fetal testing
- Fetal death
- Lethal anomaly or extreme prematurity
- Reverse end-diastolic flow on umbilical artery Dopplers

**Note:** In patients who have preeclampsia with severe features at 34 weeks' gestation or more, delivery is recommended after maternal stabilization.

HELLP = hemolysis, elevated liver enzymes, and low platelet count.

Information from reference 7.

rates of up to 97% for patients less than 28 weeks' gestation and 65% for patients 28 to 32 weeks' gestation have been reported. Decisions about the mode of delivery for patients remote from term should be individualized based on gestational age, disease progression, and fetal status.<sup>7</sup> Although antenatal corticosteroids are recommended before 34 weeks' gestation and can be considered before 37 weeks, in preeclampsia with severe features, delivery should not be delayed to complete steroid administration.<sup>26,27</sup>

**Postpartum Care**

After delivery, most people with preeclampsia experience diuresis, lower blood pressure, and general improvement. Magnesium sulfate should be continued for 24 hours postpartum. Hypertension may worsen while third-space fluid returns to the vasculature and can peak three to six days postpartum.<sup>17,29</sup> Close monitoring and outpatient follow-up within the first seven to 10 days is recommended for patients with gestational hypertension or preeclampsia.<sup>29</sup> Home blood pressure monitoring may increase the likelihood of obtaining blood pressure measurements at the recommended time, reduce hypertension-related hospital

readmissions, and narrow disparities in adherence to postpartum follow-up.<sup>30</sup>

Antihypertensive medications administered postpartum should be started or titrated to maintain a systolic blood pressure of less than 150 mm Hg and a diastolic blood pressure of less than 100 mm Hg to prevent the development of severe hypertension.<sup>24,31</sup> Antihypertensive medications are safe during lactation, although thiazides may decrease milk volume.<sup>4,16,17</sup> Treatment of acute-onset severe hypertension follows the same protocols after delivery<sup>7</sup> (Table 3<sup>4,16</sup>). All postpartum patients should receive information about hypertensive warning signs before discharge.<sup>7,17</sup>

**Prevention**

Aspirin therapy is a safe and effective risk-reduction strategy in patients with risk factors for developing preeclampsia<sup>5,8,32,33</sup> (Table 5<sup>34</sup>). In these patients, daily low-dose aspirin (81 mg) lowers the likelihood of developing preeclampsia by 15% and decreases the risk of preterm birth, small-for-gestational-age infants, and perinatal mortality.<sup>5,8,35</sup> Aspirin should be initiated after 12 weeks' gestation (optimally before 16 weeks) and continued until delivery.<sup>5,7</sup> Calcium supplementation may decrease the risk of preeclampsia, particularly for patients with low-calcium diets; however, high-quality evidence is lacking.<sup>9,33</sup>

**Prognosis**

Hypertensive disorders of pregnancy are associated with short- and long-term maternal and fetal complications.<sup>2,5-7,11,16,36,37</sup> There is also a risk of recurrence in subsequent pregnancies.<sup>36,37</sup> Fetal and neonatal complications include low-birth-weight infants, preterm delivery, perinatal mortality, congenital malformations, and cognitive issues in childhood and beyond.<sup>5,16,37</sup> Studies suggest there is an increased risk of hypertension, obesity, and cardiovascular disease (CVD) in infants that extends into adulthood.<sup>6</sup>

People who have had hypertensive disorders of pregnancy have twice the risk of CVD throughout their lifetime compared with patients who have not, and an increased risk of stroke, heart failure, and kidney disease.<sup>5,7,11,36-38</sup> Patients with pregnancy-associated hypertension have a fivefold greater lifetime risk of hypertension and are diagnosed an average of 10 years younger than patients without pregnancy-associated hypertension.<sup>2,7</sup> These risks are higher with recurrent preeclampsia or more severe manifestations.<sup>7,16,38</sup> One explanation is that underlying endothelial dysfunction predisposes patients to hypertensive disorders of pregnancy and CVD. Physiologic stress of pregnancy and cardiovascular changes associated with hypertensive disorders of pregnancy may cause cellular remodeling that contributes to future CVD.<sup>2</sup>

TABLE 5

## Risk Assessment for Preeclampsia

Risk level	Risk factors*	Recommendation
High†	History of preeclampsia, especially when accompanied by an adverse outcome Multifetal gestation Chronic hypertension Pregestational type 1 or 2 diabetes mellitus Kidney disease Autoimmune disease (systemic lupus erythematosus, anti-phospholipid syndrome) Combination of multiple moderate-risk factors	Recommend low-dose aspirin if the patient has one or more high-risk factors
Moderate‡	Nulliparity Obesity (body mass index > 30 kg per m <sup>2</sup> ) Family history of preeclampsia (mother or sister) Black race (due to social, rather than biologic, factors)§ Lower incomes Age 35 years or older Personal history factors (e.g., low-birth-weight or small-for-gestational-age infant, previous adverse pregnancy outcome, > 10-year pregnancy interval) In vitro conception	Recommend low-dose aspirin if the patient has two or more moderate-risk factors Consider low-dose aspirin if the patient has one moderate-risk factor
Low	Prior uncomplicated term delivery without risk factors	Do not recommend low-dose aspirin

\*—Includes only risk factors obtained from the patient's medical history. Clinical measures are not included.

†—High-risk factors are associated with the greatest risk of preeclampsia. Preeclampsia incidence rate would be approximately 8% or greater in a pregnant person with one or more high-risk factors.

‡—Moderate-risk factors are independently associated with preeclampsia.

§—Factors associated with increased risk due to environmental, social, and historical inequities shaping health exposures, access to health care, and unequal resource allocation, not biologic propensities.

Adapted from U.S. Preventive Services Task Force. Aspirin use to prevent preeclampsia and related morbidity and mortality: preventive medication. September 28, 2021. Accessed January 8, 2024. <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/low-dose-aspirin-use-for-the-prevention-of-morbidity-and-mortality-from-preeclampsia-preventive-medication>.

Postpartum counseling should emphasize the importance of ongoing primary care because of the risk of future CVD. Regular health care visits should include blood pressure monitoring, the evaluation for and treatment of comorbidities such as high cholesterol, diabetes, and tobacco use, and ongoing education about a healthy lifestyle (e.g., stress reduction, sleep hygiene, weight management).<sup>37-39</sup>

This article updates previous articles on this topic by Leeman, et al.<sup>40</sup>; Leeman and Fontaine<sup>41</sup>; Wagner<sup>42</sup>; and Padden.<sup>43</sup>

**Data Sources:** PubMed searches were conducted using the key words hypertensive disorders of pregnancy, hypertension, pregnancy-induced, chronic hypertension in pregnancy, preeclampsia, and eclampsia. We used an evidence summary generated by Essential Evidence Plus with the key words hypertension, pregnancy-induced, preeclampsia, and eclampsia. We searched the Cochrane database and U.S. Preventive Services Task Force recommendations using the key words preeclampsia and hypertensive disorders of pregnancy. The search included meta-analyses, randomized controlled trials, clinical trials, and reviews. Whenever possible, if studies used race or gender as patient categories but did not define how these categories were assigned, they were not included in our final references. If studies that used these categories were determined to be essential and therefore included, limitations were stated or explanations provided in the manuscript. Search dates: December 22, 2022; January 9, 2023; February 20, 2023; and December 28, 2023.

## The Authors

**NARGES FARAH, MD**, is an associate professor in the Department of Family Medicine at the University of North Carolina School of Medicine, Chapel Hill.

**FAREEDAT OLUYADI, MD, IBCLC**, is an assistant professor in the Department of Family Medicine at Charles R. Drew University of Medicine and Science, Los Angeles, Calif.

**ANDREA B. DOTSON, MD, MSPH, IBCLC**, is an assistant professor in the Department of Family Medicine and Community Health at Duke University School of Medicine, Durham, N.C.

Address correspondence to Narges Farahi, MD, University of North Carolina at Chapel Hill, 590 Manning Dr., Chapel Hill, NC 27599 ([narges\\_farahi@med.unc.edu](mailto:narges_farahi@med.unc.edu)). Reprints are not available from the authors.

## References

1. Ford ND, Cox S, Ko JY, et al. Hypertensive disorders in pregnancy and mortality at delivery hospitalization - United States, 2017-2019. *MMWR Morb Mortal Wkly Rep*. 2022;71(17):585-591.
2. Garovic VD, Dechend R, Easterling T, et al. Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association [published correction appears in *Hypertension*. 2022;79(3):e70]. *Hypertension*. 2022;79(2):e21-e41.
3. Creanga AA, Syverson C, Seed K, et al. Pregnancy-related mortality in the United States, 2011-2013. *Obstet Gynecol*. 2017;130(2):366-373.
4. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG practice bulletin no. 203: chronic hypertension in pregnancy. *Obstet Gynecol*. 2019;133(1):e26-e50.

## HYPERTENSIVE DISORDERS OF PREGNANCY

- Henderson JT, Vesco KK, Senger CA, et al. Aspirin use to prevent preeclampsia and related morbidity and mortality: updated evidence report and systematic review for the U.S. Preventive Services Task Force. *JAMA*. 2021;326(12):1192-1206.
- Cameron NA, Everitt I, Seegmiller LE, et al. Trends in the incidence of new-onset hypertensive disorders of pregnancy in the United States, 2007 to 2019. *J Am Heart Assoc*. 2022;11(2):e023791.
- Gestational hypertension and preeclampsia. ACOG practice bulletin no. 222. *Obstet Gynecol*. 2020;135(6):e237-e260.
- Bartsch E, Medcalf KE, Park AL, et al.; High Risk of Pre-eclampsia Identification Group. Clinical risk factors for pre-eclampsia determined in early pregnancy. *BMJ*. 2016;353:i1753.
- Hofmeyr GJ, Manyame S, Medley N, et al. Calcium supplementation commencing before or early in pregnancy, for preventing hypertensive disorders of pregnancy. *Cochrane Database Syst Rev*. 2019;(9):CD011192.
- Ives CW, Sinkey R, Rajapreyar I, et al. Preeclampsia-pathophysiology and clinical presentations. *J Am Coll Cardiol*. 2020;76(14):1690-1702.
- Tita AT, Szychowski JM, Boggess K, et al.; Chronic Hypertension and Pregnancy Trial Consortium. Treatment for mild chronic hypertension during pregnancy. *N Engl J Med*. 2022;386(19):1781-1792.
- Shahul S, Tung A, Minhaj M, et al. Racial disparities in comorbidities, complications, and maternal and fetal outcomes in women with preeclampsia/eclampsia. *Hypertens Pregnancy*. 2015;34(4):506-515.
- Howell EA. Reducing disparities in severe maternal morbidity and mortality. *Clin Obstet Gynecol*. 2018;61(2):387-399.
- Petersen EE, Davis NL, Goodman D, et al. Vital signs: pregnancy-related deaths, United States, 2011-2015, and strategies for prevention, 13 states, 2013-2017. *MMWR Morb Mortal Wkly Rep*. 2019;68(18):423-429.
- Puia-Dumitrescu M, Greenberg RG, Younge N, et al. Disparities in the use of antenatal corticosteroids among women with hypertension in North Carolina. *J Perinatol*. 2020;40(3):456-462.
- Battarbee AN, Sinkey RG, Harper LM, et al. Chronic hypertension in pregnancy. *Am J Obstet Gynecol*. 2020;222(6):532-541.
- Hauspurg A, Jeyabalan A. Postpartum preeclampsia or eclampsia: defining its place and management among the hypertensive disorders of pregnancy. *Am J Obstet Gynecol*. 2022;226(2S):S1211-S1221.
- Greenberg VR, Silasi M, Lundsberg LS, et al. Perinatal outcomes in women with elevated blood pressure and stage 1 hypertension. *Am J Obstet Gynecol*. 2021;224(5):521.e1-521.e11.
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in *Hypertension*. 2018;71(6):e140-e144]. *Hypertension*. 2018;71(6):e13-e115.
- Barry MJ, Nicholson WK, Silverstein M, et al. Screening for hypertensive disorders of pregnancy: U.S. Preventive Services Task Force final recommendation statement. *JAMA*. 2023;330(11):1074-1082.
- Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. *Obstet Gynecol*. 2004;103(5 pt 1):981-991.
- Mattar F, Sibai BM. Eclampsia. VIII. Risk factors for maternal morbidity. *Am J Obstet Gynecol*. 2000;182(2):307-312.
- Indications for outpatient antenatal fetal surveillance: ACOG Committee Opinion Summary no. 828. *Obstet Gynecol*. 2021;137(6):1148-1151.
- Hypertension in pregnancy: diagnosis and management. NICE guideline no. 133. National Institute for Health and Care Excellence. 2019.
- Duley L, Gülmezoglu AM, Henderson-Smart DJ, et al. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. *Cochrane Database Syst Rev*. 2010;(11):CD000025.
- Committee on Obstetric Practice. Committee opinion no. 713: antenatal corticosteroid therapy for fetal maturation. *Obstet Gynecol*. 2017;130(2):e102-e109.
- Gyamfi-Bannerman C, Thom EA, Blackwell SC, et al.; NICHD Maternal-Fetal Medicine Units Network. Antenatal betamethasone for women at risk for late preterm delivery [published correction appears in *N Engl J Med*. 2023;388(18):1728]. *N Engl J Med*. 2016;374(14):1311-1320.
- Woudstra DM, Chandra S, Hofmeyr GJ, et al. Corticosteroids for HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome in pregnancy. *Cochrane Database Syst Rev*. 2010;(9):CD008148.
- Bernstein PS, Martin JN Jr., Barton JR, et al. National Partnership for Maternal Safety: consensus bundle on severe hypertension during pregnancy and the postpartum period [published correction appears in *Obstet Gynecol*. 2019;133(6):1288]. *Obstet Gynecol*. 2017;130(2):347-357.
- Steele DW, Adam GP, Saldanha IJ, et al. *Management of Postpartum Hypertensive Disorders of Pregnancy*. Agency for Healthcare Research and Quality; May 2023.
- Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on hypertension in pregnancy. *Obstet Gynecol*. 2013;122(5):1122-1131.
- Richards EMF, Giorgione V, Stevens O, et al. Low-dose aspirin for the prevention of superimposed preeclampsia in women with chronic hypertension. *Am J Obstet Gynecol*. 2023;228(4):395-408.
- Liu YH, Zhang YS, Chen JY, et al. Comparative effectiveness of prophylactic strategies for preeclampsia: a network meta-analysis of randomized controlled trials. *Am J Obstet Gynecol*. 2023;228(5):535-546.
- U.S. Preventive Services Task Force. Aspirin use to prevent preeclampsia and related morbidity and mortality: preventive medication. September 28, 2021. Accessed January 8, 2024. <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/low-dose-aspirin-use-for-the-prevention-of-morbidity-and-mortality-from-preeclampsia-preventive-medication>
- Davidson KW, Barry MJ, Mangione CM, et al. Aspirin use to prevent preeclampsia and related morbidity and mortality: US Preventive Services Task Force Recommendation statement. *JAMA*. 2021;326(12):1186-1191.
- Brouwers L, van der Meiden-van Roest AJ, Savelkoul C, et al. Recurrence of pre-eclampsia and the risk of future hypertension and cardiovascular disease. *BJOG*. 2018;125(13):1642-1654.
- Brown MA, Magee LA, Kenny LC, et al.; International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. *Hypertension*. 2018;72(1):24-43.
- Magee LA, Brown MA, Hall DR, et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. *Pregnancy Hypertens*. 2022;27:148-169.
- Behrens I, Basit S, Melbye M, et al. Risk of post-pregnancy hypertension in women with a history of hypertensive disorders of pregnancy: nationwide cohort study. *BMJ*. 2017;358:j3078.
- Leeman L, Dresang LT, Fontaine P. Hypertensive disorders of pregnancy. *Am Fam Physician*. 2016;93(2):121-127.
- Leeman L, Fontaine P. Hypertensive disorders of pregnancy. *Am Fam Physician*. 2008;78(1):93-100.
- Wagner LK. Diagnosis and management of preeclampsia. *Am Fam Physician*. 2004;70(12):2317-2324.
- Padden MO. HELLP syndrome: recognition and perinatal management. *Am Fam Physician*. 1999;60(3):829-839.